**3. Conclusion**

Overall, it is still uncertain if the deregulation of the tuned balance among IGF system components possesses a crucial role in the pathogenesis of preeclampsia or is just a mere consequence of the disease. From this summary of relevant research, it is not yet plausible to determine the magnitude of possible associations, if any, between varying concentrations of IGFs and IGFBPs in maternal circulation and preeclampsia risk. Hopefully, the quantification of maternal plasma levels of the peptides of the IGF family may utilize as a predictive screening test to select pregnant women at increased risk for developing preeclampsia who may be favored from the administration of aspirin or other antiplatelet therapy or more intense sonographic surveillance, optimally as the only parameter or combined with other known independent indicators of preeclampsia risk. Clearly, much additional research is warranted including longitudinal studies with serial measurements of these factors and molecular clarification of the signaling pathways of each component intending to novel diagnostic interventions and to cast further light on the pathogenesis of preeclampsia as well.

Recent Insights into the Role of the Insulin-Like Growth Factor Axis in Preeclampsia 157

Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins.

Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A,

Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL,

Giudice LC, Martina NA, Crystal RA, Tazuke S, Druzin M. Insulin-like growth factor

Giudice LC, Irwin JG. Roles of the insulin-like growth factor family in non-pregnant human

Goldman-Wohl D, Yagel S. Regulation of trophoblast invasion: from normal implantation to

Gratton RJ, Asano H, Han VKM. The regional expression of insulin-like growth factor II

Halhali A, Tovar AR, Torres N, Bourges H, Garabedian M, Larrea F. Preeclampsia is

Han VKM, Bassett N, Walton J, Challis JRG. The expression of insulin-like growth factor

Han JY, Kim YS, Cho GJ, Roh GS, et al. Altered gene expression of caspase-10, death receptro-3 and IGFBP-3 in preeclamptic placentas. Mol. Cells 2006;22:168-174. Hietala R, Pohja-Nylander P, Rutanen EM and Laatikainen T. Serum insulin-like growth

Hills FA, Elder MG, Chard T, Sullivan MH. Regulation of human villous trophoblast by

growth. J Clin Endocrinol Metab 1995;80:1548–1555.

preeclampsia. Mol Cell Endocrinol 2002;187:233-238.

of women with preeclampsia. Placenta 2002;23:303-310.

Endocrinol Metab 2000;85:1828-1833.

Clin Endocrinol Metab 1996;81:2680-2693

a multifactorial role in the human female reproductive tract. Hum Reprod Update

Vigneri R: Insulin receptor isoform A, a newly recognized, high-affinity insulinlike growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278–3288. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factor-binding

protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein kinase pathway. J Clin Endocrinol

Rosenfeld RG: Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine

binding protein-1 at the maternal-fetal interface and IGF-I, IGF-II and IGFBP-1 in the circulation of women with severe preeclampsia. Am J Obstet Gynecol

endometrium and at the decidual: trophoblast interface. Semin Reprod Endocrinol

(IGF-II) and insulin-like growth factor binding protein-1 (IGFBP-1) in the placenta

associated with low circulating levels of insulin-like growth factor I and 1,25 dihydroxyvitamin D in maternal and umbilical cord compartments. J Clin

(IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J

factor binding protein-1 at 16 weeks and subsequent preeclampsia. Obstet Gynecol

insulin-like growth factors and insulin-like growth factor-binding protein-1. J

Forbes K, Westwood M. The IGF axis and placental function. Horm Res 2008;69:129-137. Fowler DJ, Nicolaides KH, Miell JP. Insulin-like growth factor binding protein -1 (IGFBP-1):

Endocr Rev 2002; 23:824–854.

Metab 2001;86:2484-2493.

1997;176:751-757.

1999;17:13-21.

2000;95:185-189.

Endocrinol 2004;183:487-496.

2000;6;495-504.

#### **4. References**


Altinkaynak K, Aksoy H, Bakan E, Kumtepe Y. Seru IGF-I and IGFBP-3 in healthy pregnancies and patients with preeclampsia. Clin Biochem 2003;36:221-223. Anim-Nyame N, Hills FA, Sooranna SR, Steer PJ, Johnson MR. A longitudinal study of

Anim-Nyame N, Hills FA, Sooranna SR, Steer PJ, Johnson MJ. The relationship between

Bartha JL, Romero-Carmona R, Torrejon-Cardoso R, Comino-Delgado R. Insulin, insulin-like

Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review.

Boyne MS, Thame M, Bennett FI, Osmond C, Miell JP, Forrester TE. The relationship among

Chard T. Insulin-like growth factors and their binding proteins in normal and abnormal

Chellakooty M, Vangsgaard K, Larsen T, Scheike T, et al. A longitudinal study of

Cohen P, Lamson G, Okajima T, Rosenfold RG. Transfection of the human insulin-like

Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine

Crossey PA, Pillai CC, Miell JP. Altered placental development and intrauterine growth

Dalcik H, Yardimoglu M, Vural B, Dalcik C, Filiz S, Gonca S, Kokturk S, Ceylan S:

Davison JM, Homuth V, Jeyabalan A, Conrad KP, et al. New aspects in the pathophysiology

De Groot CJM, O'Brien TJ and Taylor RN. Biochemical evidence of impaired trophoblastic

Fant M, Salafia C, Baxter RC, Schwander J, Vogel C, Pezzullo J, Moya F. Circulating levels of

retarded human fetuses. Acta Histochem 2001;103:195–207.

of preeclampsia. J Am Soc Nephrol 2004;15:2440-2448.

Efstratiadis A: Genetics of mouse growth. Int J Dev Biol 1998;42:955–976.

preeclampsia. Gynecol Endocrinol 2003;17:471-476.

hypertension. Am J Obstet Gynecol 2002;187:735-740

human fetal growth. Growth Regul 1994;4:91–100.

growth. J Clin Endocrinol Metab 2003;89:384-391.

growth. Mol Endocrinol 1993;7:380-386.

Prenat Diagn 2007;27:264-271.

Gynecol 1996;175:24-29.

growth. Regul Pept 1993;48:29-39.

Hormone Research 1994;42:140-44.

maternal plasma insulin-like growth factor binding protein-1 concentrations during normal pregnancy and pregnancies complicated by preeclampsia. Hum Reprod

insulin and insulin-like growth factor binding protein-1 is modified by

growth factor-1, and insulin resistance in women with pregnancy-induced

circulating insulin-like growth factor (IGF)-I, IGF-binding proteins-1 and -2, and birth anthropometry: a prospective study. J Clin Endocrinol Metab 2003;88:1687-

intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal

growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular

fetal growth restriction through their roles in the insulin-like growth factor system.

restriction in IGF binding protein-1 transgenic mice. J Clin Invest 2002;110:411– 418.

Expression of insulin-like growth factor in the placenta of intrauterine growth-

invasion of decidual stroma in women destined to have preeclampsia. Am J Obstet

IGFs and IGF binding proteins in human cord serum: relationships to intrauterine

**4. References** 

2000;15:2215-2219.

1691.


Recent Insights into the Role of the Insulin-Like Growth Factor Axis in Preeclampsia 159

Modric T, Silha JV, Shi Z, Gui Y, Suwanichkul A, Durham SK, Powell DR, Murphy LJ.

Moy E, Kimzey LM, Nelson LM, Blithe DL. Glycoprotein hormone α-subunit functions

Ning Y, Williams MA, Vadachkoria S, Muy-Rivera M, Frederick IO, Luthy DA. Maternal

Olausson H, Lof M, Brismar K, Lewitt M, Forsum E, Sohlstrom A. Longitudinal study of the

Osorio M, Torres J, Moya F, Pezzullo J, Salafia C, Baxter R, Schwander J, Fant M: Insulin-

Poon LCY, Staboulidou I, Maiz N, Plascencia W, Nicolaides KH. Hypertesive disorders in

Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum

Powell DR, Allander SV, Scheimann AO, Wasserman RM, Durham SK, Suwanichkul A.

Ritvos O, Ranta T, Jalkanen J, et al. Insulin-like growth factor (IGF) binding proteins from

Schiessl B, Strasburger CJ, Bidlingmaier M, et al. Role of placental growth hormone in the

Sheikh S, Satoskar P, Bhartiya D: Expression of insulin-like growth factor-I and placental

relation to fetal and infant weight. Horm Res 2008;69:99-106.

preeclampsia. Growth Horm IGF Res 2006;16:290-296.

promoter. Prog Growth Factor Res 1995;6:93-101.

choriocarcinoma cells. Endocrinology 1989;122:2150-2157.

overexpression in transgenic mice. Endocrinology 2001;142:1958–1967. Monzavi R, Cohen P. IGFs and IGFBPs: role in health and disease. Best practice and research

clinical endocrinology and metabolism 2002;16:433-447.

reproduction. Endocrinology 1996;137:1332-1339.

Clinical Biochemistry 2004;37:968-973.

Gynecol 2009a;34:142-148.

Gynecol 2009b;33:23-33.

316

Phenotypic manifestations of insulin-like growth factor-binding protein-3

synergistically with progesterone to stimulate differentiation of cultured human endometrial stromal cells to decidualized cells: a novel role for free subunit in

plasma concentrations of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in early pregnancy and subsequent risk of preeclampsia.

materanl insulin-like growth factor system before, during and after pregnancy in

like growth factors (IGFs) and IGF binding proteins-1, -2, and -3 in newborn serum: relationships to fetoplacental growth at term. Early Hum Dev 1996; 46: 15–26. Papadopoulou E, Sifakis S, Giahnakis E, Fragouli Y, Karkavitsas N, Koumantakis E,

Kalmanti M. Increased human placental growth hormone at midtrimester pregnancies may be an index of intrauterine growth retardation related to

pregnancy: screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet

pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet

Multiple proteins bind the insulin response element in the human IGFBP-1

human decidua inhibits the binding and biological action of IGF-I in cultured

alteration of maternal arterial resistance in pregnancy. J Reprod Med 2007;52:313-

growth hormone mRNA in placentae: a comparison between normal and intrauterine growth retardation pregnancies. Mol Hum Reprod 2001;7:287–292. Shin JC, Lee JH, Yang DE, Moon HB, Rha JG, Kim SP. Expression of insulin-like frowth

factor-II and insulin-like growth factor binding protein-1 in the placental basal plate from pre-eclamptic pregnancies. Int J Gynaecol Obstet 2003;81:273-280. Sifakis S, Papadopoulou E, Konstantinidou A, Giahnakis E, Fragouli Y, Karkavitsas N,

Koumantakis E, Kalmanti M. Increased levels of human placental growth hormone


Holly JMP, Biddlecombe RA, Dunger DB et al. Circadian variation of GH- independent IGF-

Holmes R, Montemagno R, Jones J, Preece M, Rodeck C, Soothill P: Fetal and maternal

Hubinette A, Lichtenstein P, Brismar K, Vatten L, Jacobsen G, Ekbom A, Cnattingius S.

Jones JL, Gockerman A, Busby WH, Jr, Wright G, Clemmons DR. Insulin-like growth factor

Jones JI and Clemmons DR. Insulin-like growth factors and their binding proteins. Endocr

Kocyigit Y, Bayhan G, Atamer A, Atamer Y. Serm leves of leptin, insulin-like growth factor-I

their relationship to insulin resistance. Gynecol Endocrinol 2004;18:341-348. Lacey H, Haigh T, Westwood M, Aplin JD: Mesenchymally-derived insulin-like growth

Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL: Loss of the imprinted

Lewitt MS, Scott FP, Clarke NM, Wu T, Sinosich MJ, Baxter RC. Regulation of insulin-like

Lindsay RS, Westgate JA, Beattie J, Pattison NS, Gamble G, Mildenhall LF, Breier BH,

Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and

Miller AG, Aplin JD, Westwood M: Adenovirally mediated expression of insulin-like

Mittal P, Espinoza J, Hassan S, et al. Placental growth hormone is increased in the maternal

overgrowth and perinatal lethality. Genes Dev 1994;8:2953–2963.

appropriate or retarded fetal growth. Early Hum Dev 1997;49:7–17.

insulin? Clin Endocrinol (Oxf) 1988;29:667-675.

10557.

2002;2:5.

Rev 1994;18:1-31.

of Endocrinology 1998;159:265-274.

Endocrinol Metab 2005;90:379–385.

Ultrasound Obstet Gynecol 2001;18:583-586.

Endocrinol 2007;66:322-328.

2007;20:651-9.

binding protein in diabetes mellitus and its relationship to insulin. A new role for

plasma insulin-like growth factors and binding proteins in pregnancies with

Serum insulin-like growth factors in normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2003;82:1004-1009. Ingec M, Gursoy HG, Yildiz L, Kumtepe Y, Kadanali S. Serum levels of insulin, IGF-I, and IGFBP-1 in preeclampsia and eclampsia. Int J Gynaecol Obstet 2004;84:214-219. Irwin JC, Suen LF, Faessen GH, Popovici RM, Giudice LC. Insulin-like growth factor (IGF)-

II inhibition of endometrial stroma cell tissue inhibitor of metalloproteinase-3 and IGF-binding protein-1 suggests paracrine interactions at the decidua: trophoblast interface during human implantation. J Clin Endocrionol Metab 2001;86:2060-2064.

binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 1993;90:10553-

and insulin-like growth factor binding protein-3 in women with pre-eclampsia, and

factor 1 provides a paracrine stimulus for trophoblast migration. BMC Dev Biol

IGF2/cation-independent mannose 6-phosphate receptor results in fetal

growth factor-binding protein-3 ternary complex formation in pregnancy. Journal

Johnstone FD. Inverse changes in fetal insulin-like growth factor (IGF)-1 and IGF binding protein-1 in association with higher birth weight in maternal diabetes. Clin

fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation.

growth factors enhances the function of first trimester placental fibroblasts. J Clin

and fetal serum of patients with preeclampsia. J Matern Fetal Neonatal Med


**10** 

*France* 

**Blood Parameters in Human Fetuses with** 

Fabienne Champion2, François Golfier2, Jean Pichot1 and André Revol3

Congenital malformations can be defined as structural anomalies arising during the periods

However, during the fetal period, various external factors of infectious, vascular or toxic origin can also interfere with the development of previously formed structures (Gallot,

The causes of malformations are either endogenous (genetic) or exogenous, and there are probably interactions between the genetic and the exogenous factors (Roux, 2001). The precise cause of the malformation process, however, is most often unknown and the

The biology of fetal blood has been widely described in cases of isolated intra-uterine growth restriction (Cox et al., 1988; Economides et al., 1989; Weiner et al., 1989; Pardi et al., 1989; Roberts et al., 1999) but few studies have been conducted in fetuses with morphological anomalies (Bocconi, 1997; Lallata, 1998), and their biochemical profile

We present the results of a study on 53 pregnancies with the complication of congenital malformations of variable expression and severity, and during which a fetal blood sampling was performed for fetal karyotyping. The gestational age ranged from 21 to 38 weeks of amenorrhea (average age: 28.5 ±4.45 WA). The karyotype proved to be normal for all the

The acid-base balance (pH, pCO2, bicarbonate concentration) and the oxygenation level of the fetuses (pO2, SaO2) were evaluated on umbilical venous blood (UVB), taken by cordocentesis. At the same time, the glucose, lactate, free fatty acid, aceto-acetate, betahydroxybutyrate and cholesterol concentrations were measured, being essential biochemical

underlying physiopathological mechanisms are not elucidated (Brent, 1986).

**1. Introduction** 

remains little known.

fetuses in this group.

2002).

of embryogenesis and organogenesis (Roux, 2001).

constituents in relation to the nutritional status.

*2Department of Gynecology – Obstetrics, Hospital Lyon-Sud, Pierre-Bénite Cedex* 

*3Department of Biochemistry, Hospital Lyon-Sud, Pierre-Bénite Cedex* 

**Congenital Malformations and** 

Chantal Bon1, Daniel Raudrant2, Françoise Poloce1,

*1Department of Biochemistry, Hospital Croix-Rousse, Lyon* 

**Normal Karyotype** 

in the amniotic fluid of pregnancies affected by Down syndrome. Growth Horm IGF Res 2009;19:121-125.


Chantal Bon1, Daniel Raudrant2, Françoise Poloce1, Fabienne Champion2, François Golfier2, Jean Pichot1 and André Revol3 *1Department of Biochemistry, Hospital Croix-Rousse, Lyon 2Department of Gynecology – Obstetrics, Hospital Lyon-Sud, Pierre-Bénite Cedex 3Department of Biochemistry, Hospital Lyon-Sud, Pierre-Bénite Cedex France* 
